{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:19:38Z","timestamp":1793315978925,"version":"4.5.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T00:00:00Z","timestamp":1718150400000},"content-version":"vor","delay-in-days":11,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Despite recent therapeutic advances, metastatic castration-resistant prostate cancer (mCRPC) remains lethal. Chimeric antigen receptor (CAR) T cell therapies have demonstrated durable remissions in hematological malignancies. We report results from a phase 1, first-in-human study of prostate stem cell antigen (PSCA)-directed CAR T cells in men with mCRPC. The starting dose level (DL) was 100 million (M) CAR T cells without lymphodepletion (LD), followed by incorporation of LD. The primary end points were safety and dose-limiting toxicities (DLTs). No DLTs were observed at DL1, with a DLT of grade 3 cystitis encountered at DL2, resulting in addition of a new cohort using a reduced LD regimen\u2009+\u2009100\u2009M CAR T cells (DL3). No DLTs were observed in DL3. Cytokine release syndrome of grade 1 or 2 occurred in 5 of 14 treated patients. Prostate-specific antigen declines (&gt;30%) occurred in 4 of 14 patients, as well as radiographic improvements. Dynamic changes indicating activation of peripheral blood endogenous and CAR T cell subsets, TCR repertoire diversity and changes in the tumor immune microenvironment were observed in a subset of patients. Limited persistence of CAR T cells was observed beyond 28 days post-infusion. These results support future clinical studies to optimize dosing and combination strategies to improve durable therapeutic outcomes. ClinicalTrials.gov identifier\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT03873805\">NCT03873805<\/jats:ext-link>\n                    .\n                  <\/jats:p>","DOI":"10.1038\/s41591-024-02979-8","type":"journal-article","created":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T06:02:47Z","timestamp":1718172167000},"page":"1636-1644","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":150,"title":["PSCA-CAR T cell therapy in metastatic castration-resistant prostate cancer: a phase 1 trial"],"prefix":"10.1038","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5990-298X","authenticated-orcid":false,"given":"Tanya B.","family":"Dorff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Suzette","family":"Blanchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren N.","family":"Adkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Luebbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neena","family":"Leggett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie N.","family":"Shishido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Macias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marissa M.","family":"Del Real","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurav","family":"Dhapola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colt","family":"Egelston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0637-2414","authenticated-orcid":false,"given":"John P.","family":"Murad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0984-8959","authenticated-orcid":false,"given":"Reginaldo","family":"Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinny","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ammar","family":"Chaudhry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hripsime","family":"Martirosyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan","family":"Gerdts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie R.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracey","family":"Stiller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dileshni","family":"Tilakawardane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1712-0848","authenticated-orcid":false,"given":"Sumanta","family":"Pal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catalina","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert E.","family":"Reiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1464-5494","authenticated-orcid":false,"given":"Lihua E.","family":"Budde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8146-0997","authenticated-orcid":false,"given":"Massimo","family":"D\u2019Apuzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kuhn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lior","family":"Pachter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2803-4152","authenticated-orcid":false,"given":"Stephen J.","family":"Forman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8136-2112","authenticated-orcid":false,"given":"Saul J.","family":"Priceman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,12]]},"reference":[{"key":"2979_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel, R. L., Miller, K. D., Fuchs, H. E. & Jemal, A. Cancer statistics, 2021. CA Cancer J. Clin. 71, 7\u201333 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"2979_CR2","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1002\/cncr.23669","volume":"113","author":"CS Higano","year":"2008","unstructured":"Higano, C. S. et al. Phase 1-2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. Cancer 113, 975\u2013984 (2008).","journal-title":"Cancer"},{"key":"2979_CR3","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1200\/JCO.18.02031","volume":"37","author":"JL Gulley","year":"2019","unstructured":"Gulley, J. L. et al. Phase III trial of PROSTVAC in asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. J. Clin. Oncol. 37, 1051\u20131061 (2019).","journal-title":"J. Clin. Oncol."},{"key":"2979_CR4","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1200\/JCO.19.01638","volume":"38","author":"ES Antonarakis","year":"2020","unstructured":"Antonarakis, E. S. et al. Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study. J. Clin. Oncol. 38, 395\u2013405 (2020).","journal-title":"J. Clin. Oncol."},{"key":"2979_CR5","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/S1470-2045(14)70189-5","volume":"15","author":"ED Kwon","year":"2014","unstructured":"Kwon, E. D. et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 15, 700\u2013712 (2014).","journal-title":"Lancet Oncol."},{"key":"2979_CR6","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1001294","volume":"363","author":"PW Kantoff","year":"2010","unstructured":"Kantoff, P. W. et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363, 411\u2013422 (2010).","journal-title":"N. Engl. J. Med."},{"key":"2979_CR7","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1158\/1078-0432.CCR-21-1483","volume":"28","author":"TB Dorff","year":"2022","unstructured":"Dorff, T. B. et al. Novel redirected T-cell immunotherapies for advanced prostate cancer. Clin. Cancer Res. 28, 576\u2013584 (2022).","journal-title":"Clin. Cancer Res."},{"key":"2979_CR8","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1038\/sj.onc.1203426","volume":"19","author":"Z Gu","year":"2000","unstructured":"Gu, Z. et al. Prostate stem cell antigen (PSCA) expression increases with high Gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene 19, 1288\u20131296 (2000).","journal-title":"Oncogene"},{"key":"2979_CR9","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1380764","volume":"7","author":"SJ Priceman","year":"2017","unstructured":"Priceman, S. J. et al. Co-stimulatory signaling determines tumor antigen sensitivity and persistence of CAR T cells targeting PSCA+ metastatic prostate cancer. Oncoimmunology 7, e1380764 (2017).","journal-title":"Oncoimmunology"},{"key":"2979_CR10","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1016\/j.ymthe.2021.02.024","volume":"29","author":"JP Murad","year":"2021","unstructured":"Murad, J. P. et al. Pre-conditioning modifies the TME to enhance solid tumor CAR T cell efficacy and endogenous protective immunity. Mol. Ther. 29, 2335\u20132349 (2021).","journal-title":"Mol. Ther."},{"key":"2979_CR11","doi-asserted-by":"publisher","first-page":"758","DOI":"10.3390\/cancers14030758","volume":"14","author":"SN Shishido","year":"2022","unstructured":"Shishido, S. N. et al. Characterization of cellular and acellular analytes from pre-cystectomy liquid biopsies in patients newly diagnosed with primary bladder cancer. Cancers 14, 758 (2022).","journal-title":"Cancers"},{"key":"2979_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-022-00480-4","volume":"8","author":"SM Setayesh","year":"2022","unstructured":"Setayesh, S. M. et al. Multianalyte liquid biopsy to aid the diagnostic workup of breast cancer. NPJ Breast Cancer 8, 112 (2022).","journal-title":"NPJ Breast Cancer"},{"key":"2979_CR13","doi-asserted-by":"publisher","first-page":"3007","DOI":"10.3390\/cancers14123007","volume":"14","author":"SN Shishido","year":"2022","unstructured":"Shishido, S. N. et al. Liquid biopsy landscape in patients with primary upper tract urothelial carcinoma. Cancers 14, 3007 (2022).","journal-title":"Cancers"},{"key":"2979_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21619-0","volume":"12","author":"T Yamauchi","year":"2021","unstructured":"Yamauchi, T. et al. T cell CX3CR1 expression as a dynamic blood-based biomarker of response to immune checkpoint inhibitors. Nat. Commun. 12, 1402 (2021).","journal-title":"Nat. Commun."},{"key":"2979_CR15","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377, 2531\u20132544 (2017).","journal-title":"N. Engl. J. Med."},{"key":"2979_CR16","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude, S. L. et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N. Engl. J. Med. 378, 439\u2013448 (2018).","journal-title":"N. Engl. J. Med."},{"key":"2979_CR17","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","volume":"377","author":"SJ Schuster","year":"2017","unstructured":"Schuster, S. J. et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N. Engl. J. Med. 377, 2545\u20132554 (2017).","journal-title":"N. Engl. J. Med."},{"key":"2979_CR18","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1097\/01.ju.0000064929.43602.17","volume":"169","author":"L Cheng","year":"2003","unstructured":"Cheng, L. et al. Immunocytochemical analysis of prostate stem cell antigen as adjunct marker for detection of urothelial transitional cell carcinoma in voided urine specimens. J. Urol. 169, 2094\u20132100 (2003).","journal-title":"J. Urol."},{"key":"2979_CR19","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1177\/1078155220920690","volume":"27","author":"HM Almalag","year":"2021","unstructured":"Almalag, H. M. et al. Incidence of hemorrhagic cystitis after cyclophosphamide therapy with or without mesna: a cohort study and comprehensive literature review. J. Oncol. Pharm. Pract. 27, 340\u2013349 (2021).","journal-title":"J. Oncol. Pharm. Pract."},{"key":"2979_CR20","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/s41571-022-00607-3","volume":"19","author":"L Amini","year":"2022","unstructured":"Amini, L. et al. Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion. Nat. Rev. Clin. Oncol. 19, 342\u2013355 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2979_CR21","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.omto.2020.06.014","volume":"18","author":"J Alzubi","year":"2020","unstructured":"Alzubi, J. et al. PSMA-directed CAR T cells combined with low-dose docetaxel treatment induce tumor regression in a prostate cancer xenograft model. Mol. Ther. Oncolytics 18, 226\u2013235 (2020).","journal-title":"Mol. Ther. Oncolytics"},{"key":"2979_CR22","doi-asserted-by":"publisher","first-page":"e25962","DOI":"10.4161\/onci.25962","volume":"2","author":"MH Kershaw","year":"2012","unstructured":"Kershaw, M. H., Devaud, C., John, L. B., Westwood, J. A. & Darcy, P. K. Enhancing immunotherapy using chemotherapy and radiation to modify the tumor microenvironment. Oncoimmunology 2, e25962 (2012).","journal-title":"Oncoimmunology"},{"key":"2979_CR23","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/s41591-022-01726-1","volume":"28","author":"V Narayan","year":"2022","unstructured":"Narayan, V. et al. PSMA-targeting TGFb-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial. Nat. Med. 28, 724\u2013734 (2022).","journal-title":"Nat. Med."},{"key":"2979_CR24","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1097\/PPO.0000000000000035","volume":"20","author":"SL Maude","year":"2014","unstructured":"Maude, S. L. et al. Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J. 20, 119\u2013122 (2014).","journal-title":"Cancer J."},{"key":"2979_CR25","doi-asserted-by":"publisher","unstructured":"Slovin S. F. et al. Phase 1 study of P-PSMA-101 CAR-T cells in patients with metastatic castration-resistant prostate cancer. J. Clin. Oncol. https:\/\/doi.org\/10.1200\/JCO.2022.40.6_suppl.098 (2022).","DOI":"10.1200\/JCO.2022.40.6_suppl.098"},{"key":"2979_CR26","doi-asserted-by":"publisher","unstructured":"Stein M. N. et al. Early results from a phase 1, multicenter trial of PSCA-specific GoCAR T cells (BPX-601) in patients with metastatic castration-resistant prostate cancer (mCRPC). J. Clin. Oncol. https:\/\/doi.org\/10.1200\/JCO.2023.41.6_suppl.140 (2023).","DOI":"10.1200\/JCO.2023.41.6_suppl.140"},{"key":"2979_CR27","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1158\/1078-0432.CCR-22-2038","volume":"29","author":"I Aldoss","year":"2023","unstructured":"Aldoss, I. et al. Favorable activity and safety profile of memory-enriched CD19-targeted chimeric antigen receptor T-cell therapy in adults with high-risk relapsed\/refractory ALL. Clin. Cancer Res. 29, 742\u2013753 (2023).","journal-title":"Clin. Cancer Res."},{"key":"2979_CR28","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s40425-017-0227-4","volume":"5","author":"R Urak","year":"2017","unstructured":"Urak, R. et al. Ex vivo Akt inhibition promotes the generation of potent CD19 CAR T cells for adoptive immunotherapy. J. Immunother. Cancer 5, 26 (2017).","journal-title":"J. Immunother. Cancer"},{"key":"2979_CR29","doi-asserted-by":"publisher","first-page":"e007002","DOI":"10.1136\/jitc-2023-007002","volume":"11","author":"V Mehra","year":"2023","unstructured":"Mehra, V. et al. AKT inhibition generates potent polyfunctional clinical grade AUTO1 CAR T-cells, enhancing function and survival. J. Immunother. Cancer 11, e007002 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"2979_CR30","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","volume":"19","author":"S Depil","year":"2020","unstructured":"Depil, S., Duchateau, P., Grupp, S. A., Mufti, G. & Poirot, L. 'Off-the-shelf' allogeneic CAR T cells: development and challenges. Nat. Rev. Drug Discov. 19, 185\u2013199 (2020).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2979_CR31","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.semcancer.2022.05.007","volume":"86","author":"S Liu","year":"2022","unstructured":"Liu, S., Alabi, B. R., Yin, Q. & Stoyanova, T. Molecular mechanisms underlying the development of neuroendocrine prostate cancer. Semin. Cancer Biol. 86, 57\u201368 (2022).","journal-title":"Semin. Cancer Biol."},{"key":"2979_CR32","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1158\/1078-0432.CCR-20-3396","volume":"27","author":"DC DeLucia","year":"2021","unstructured":"DeLucia, D. C. et al. Regulation of CEACAM5 and therapeutic efficacy of an anti-CEACAM5-SN38 antibody-drug conjugate in neuroendocrine prostate cancer. Clin. Cancer Res. 27, 759\u2013774 (2021).","journal-title":"Clin. Cancer Res."},{"key":"2979_CR33","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1158\/2159-8290.CD-21-0407","volume":"11","author":"PS Adusumilli","year":"2021","unstructured":"Adusumilli, P. S. et al. A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 antibody agent pembrolizumab. Cancer Discov. 11, 2748\u20132763 (2021).","journal-title":"Cancer Discov."},{"key":"2979_CR34","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.cct.2010.09.011","volume":"32","author":"MS Blanchard","year":"2011","unstructured":"Blanchard, M. S. & Longmate, J. A. Toxicity equivalence range design (TEQR): a practical phase I design. Contemp. Clin. Trials 32, 114\u2013121 (2011).","journal-title":"Contemp. Clin. Trials"},{"key":"2979_CR35","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1158\/1541-7786.MCR-21-0383","volume":"19","author":"S Chai","year":"2021","unstructured":"Chai, S. et al. Platelet-coated circulating tumor cells are a predictive biomarker in patients with metastatic castrate-resistant prostate cancer. Mol. Cancer Res. 19, 2036\u20132045 (2021).","journal-title":"Mol. Cancer Res."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-02979-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-02979-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-02979-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T10:20:56Z","timestamp":1718792456000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-02979-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["2979"],"URL":"https:\/\/doi.org\/10.1038\/s41591-024-02979-8","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"2 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T.B.D. is a consultant for AstraZeneca and Janssen. S.J.P. and S.J.F. are scientific advisors to and receive royalties from Mustang Bio. S.J.P. is also a scientific advisor and\/or receives royalties from Imugene, Adicet Bio, Port Therapeutics and Celularity. S.J.P. and S.J.F. are listed as co-inventors on a patent on chimeric antigen receptors targeted to PSCA, which is owned by the City of Hope. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}